Anthony Carona, David Jacobson, Charles Hildebolt, Kevin Rowland
{"title":"A systematic review and meta-analysis of alpha-adrenergic antagonists for the treatment of pain in chronic prostatitis.","authors":"Anthony Carona, David Jacobson, Charles Hildebolt, Kevin Rowland","doi":"10.1007/s00345-025-05575-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a debilitating condition affecting 2-10% of men globally. Its symptoms, including pelvic pain, urinary problems, and reduced quality of life, vary widely. Despite extensive research, a definitive treatment remains elusive. Alpha-adrenergic antagonists are frequently used to manage urinary symptoms, while analgesics are employed for pain. However, the long-term efficacy of alpha-adrenergic antagonists for pelvic pain requires further investigation. CP/CPPS places a significant burden on healthcare systems and the economy. This systematic review aims to evaluate the effectiveness of alpha-adrenergic antagonists in reducing pain symptoms in men with CP/CPPS compared to placebo.</p><p><strong>Methods: </strong>A systematic search of randomized, placebo-controlled trials evaluating the effectiveness of alpha-adrenergic antagonists for the treatment of pain in CP/CPPS was conducted and captured all available studies (n = 680). After application of exclusion criteria, five studies were identified as suitable for inclusion.</p><p><strong>Results: </strong>Four papers consisting of five studies, containing a total of 578 participants, were evaluated. The combined effects found no difference in pain relief between treated and control subjects for the data from the five studies in the meta-analysis (P = 0.106), with the 95% CI for the random effects model containing a value of 0.00.</p><p><strong>Conclusion: </strong>In adults with CP/CPPS, alpha-adrenergic antagonists were ineffective as monotherapy to treat pain. Further studies are needed to address possible confounding variables for alpha-adrenergic antagonist efficacy. These findings suggest that alpha-adrenergic antagonists as monotherapy are not effective for pain reduction in CP/CPPS and highlight the need for further research to explore combination therapies or other treatment modalities.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"204"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00345-025-05575-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a debilitating condition affecting 2-10% of men globally. Its symptoms, including pelvic pain, urinary problems, and reduced quality of life, vary widely. Despite extensive research, a definitive treatment remains elusive. Alpha-adrenergic antagonists are frequently used to manage urinary symptoms, while analgesics are employed for pain. However, the long-term efficacy of alpha-adrenergic antagonists for pelvic pain requires further investigation. CP/CPPS places a significant burden on healthcare systems and the economy. This systematic review aims to evaluate the effectiveness of alpha-adrenergic antagonists in reducing pain symptoms in men with CP/CPPS compared to placebo.
Methods: A systematic search of randomized, placebo-controlled trials evaluating the effectiveness of alpha-adrenergic antagonists for the treatment of pain in CP/CPPS was conducted and captured all available studies (n = 680). After application of exclusion criteria, five studies were identified as suitable for inclusion.
Results: Four papers consisting of five studies, containing a total of 578 participants, were evaluated. The combined effects found no difference in pain relief between treated and control subjects for the data from the five studies in the meta-analysis (P = 0.106), with the 95% CI for the random effects model containing a value of 0.00.
Conclusion: In adults with CP/CPPS, alpha-adrenergic antagonists were ineffective as monotherapy to treat pain. Further studies are needed to address possible confounding variables for alpha-adrenergic antagonist efficacy. These findings suggest that alpha-adrenergic antagonists as monotherapy are not effective for pain reduction in CP/CPPS and highlight the need for further research to explore combination therapies or other treatment modalities.
期刊介绍:
The WORLD JOURNAL OF UROLOGY conveys regularly the essential results of urological research and their practical and clinical relevance to a broad audience of urologists in research and clinical practice. In order to guarantee a balanced program, articles are published to reflect the developments in all fields of urology on an internationally advanced level. Each issue treats a main topic in review articles of invited international experts. Free papers are unrelated articles to the main topic.